D(
Therapeutic Areas
Summit Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Ivonescimab (AK112) + Chemotherapy | Metastatic Non-Squamous NSCLC (1L, no actionable mutations) | Phase III |
| Ivonescimab (AK112) | NSCLC previously treated with PD-(L)1 inhibitor | Phase II |